ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

selexipag

Also written as “Selexipag”, “selexipag (Uptravi)” and “Selexipag Film Coated Tablets (T1)”.

Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Hypertension · Scleroderma, Systemic · Sarcoidosis, led by 2 companies.

Drug pageSelexipag: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 6, 201723 company-led studies, 3 open or runningNext primary completion: Jan 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only213 open or runningphase 4since Mar 6, 2017Apr 2, 2010Jan 31, 2027phase 3 · NCT05179876
Humanis Saglık Anonim Sirketi20 open or runningphase 1since Apr 10, 2025Apr 10, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Humanis Saglık Anonim Sirketi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 10, 2025First study: phase 1 study in Pulmonary Arterial HypertensionFirst studyNCT06932198 · 14 enrolled · Jordan
  2. Jul 3, 2026Phase 1 study in HypertensionNCT07694128 · 30 enrolled · India

TargetBeta

PTGIR →read by rule
“Prostanoid IP receptor agonist”ChEMBL 37, by rule

Other programs on PTGIR

ProgramCompanyFurthest phaseStudies
treprostinilruleUnited Therapeuticsphase 473

Studies

All 2 Humanis Saglık Anonim Sirketi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07694128Hypertension · India1CompletedJun 16, 202630
NCT06932198Pulmonary Arterial Hypertension · Jordan1CompletedMar 3, 202514

How it is read

Names in the registry

  • “Selexipag”, 13 entries
  • “selexipag”, 2 entries
  • “selexipag (Uptravi)”, 1 entry
  • “Selexipag Film Coated Tablets (T1)”, 1 entry
  • “Selexipag Film Coated Tablets (T2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.